616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy

Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study

A Phase 1 2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed refractory KMT2A rearanged NPM1 mutant and NUP98 rearranged acute leukemias

ITCC 101 APAL2020D A randomized Phase 3 trial of fludarabine cytarabine gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia

A phase 1 1b open label dose escalation first in human study to evaluate the safety tolerability pharmacokinetics and preliminary anti leukemic activity of the orally available clk inhibitor BH 30236 in adults with R R AML or HR MDS

Phase 1b study of HC 7366 alone and in combination with venetoclax and azacitidine in relapsed refractory Acute Myeloid Leukemia

A phase 1 2 study of GB3226 a novel dual inhibitor of ENL yeats  and FLT3 in patients with relapsed refractory Acute Myeloid Leukemia

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Results of the Phase 1B study of pegargiminase ADI PEG 20 in combination with AZA VEN in newly diagnosed high risk AML patients not candidates for intensive chemotherapy

A phase I study of the T cell receptor like antibody Hu8F4 in pts with advanced myeloid neoplasms

BMS 986397 a first in class casein kinase 1α CK1α degrader in patients with relapsed refractory R R acute myeloid leukemia AML and high risk myelodysplastic syndrome HR MDS A phase 1 dose escalation study

Results of the APG2575AU101 Study of lisaftoclax APG 2575 combined with azacitidine AZA in patients with newly diagnosed ND or prior venetoclax–exposed myeloid malignancies

Effiefficacy and safety of allogeneic CD123 CAR NK cell therapy in Relapsed Refractory Acute Myeloid Leukemia